Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Opyl Ltd. ( (AU:OPL) ) just unveiled an update.
Opyl Limited has successfully completed a $1.5 million oversubscribed placement to accelerate the growth of its AI-driven drug discovery platform, Trialkey. The funds will be used to enhance sales, marketing, and infrastructure, reflecting strong investor confidence in the platform’s potential to revolutionize clinical trial design. The placement was supported by key investors, including Director Antanas Guoga, and involved issuing shares at a discount, with further approvals pending for additional shares and options.
More about Opyl Ltd.
Opyl Limited operates in the technology sector, focusing on artificial intelligence solutions for drug discovery. Their primary product, Trialkey, is an AI-powered platform aimed at enhancing clinical trial design and execution, targeting global markets.
YTD Price Performance: 30.0%
Average Trading Volume: 213,717
Technical Sentiment Signal: Hold
Current Market Cap: A$5.02M
See more insights into OPL stock on TipRanks’ Stock Analysis page.